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Background: A two-year longitudinal study composed of morphometric MRI measures and cognitive behavioral
evaluation was performed on a transgenic Huntington’s disease (HD) monkey. rHD1, a transgenic HD monkey
expressing exon 1 of the human gene encoding huntingtin (HTT) with 29 CAG repeats regulated by a human
polyubiquitin C promoter was used together with four age-matched wild-type control monkeys. This is the first
study on a primate model of human HD based on longitudinal clinical measurements.
Results: Changes in striatal and hippocampal volumes in rHD1 were observed with progressive impairment in
motor functions and cognitive decline, including deficits in learning stimulus-reward associations, recognition memory
and spatial memory. The results demonstrate a progressive cognitive decline and morphometric changes in the
striatum and hippocampus in a transgenic HD monkey.
Conclusions: This is the first study on a primate model of human HD based on longitudinal clinical
measurements. While this study is based a single HD monkey, an ongoing longitudinal study with additional HD
monkeys will be important for the confirmation of our findings. A nonhuman primate model of HD could
complement other animal models of HD to better understand the pathogenesis of HD and future development
of diagnostics and therapeutics through longitudinal assessment.Background
Huntington’s disease (HD) is an autosomal dominant
neurodegenerative disorder caused by the expansion of a
CAG triplet repeat in exon 1 of the huntingtin (HTT)
gene, translated into a polyglutamine tract in the HTT
protein. HD is a devastating disorder with progressive
decline in motor, cognitive and psychiatric functions.
Motor impairment, such as chorea, is one of the earliest
clinical signs for diagnosis, whereas cognitive decline
and psychiatric disturbances often precede the onset of
motor dysfunction [1-11]. Although individual mutation
status can be determined by genetic testing, currently avail-
able treatments are limited to symptomatic management* Correspondence: awchan@emory.edu; jbachev@emory.edu
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unless otherwise stated.to improve the patients’ well-being. Treatment does not
alter or arrest the progressive development of dementia,
bradykinesia, incoordination and rigidity that leads to
disability [9,12,13].
In order to identify targets for developing and validat-
ing novel therapeutic approaches and new drugs for
genetic and biochemical intervention, animal models
including insects, rodents and large animal models such
as ovine, pig and monkey have been developed [14-20].
Although these model systems have been useful in
explaining HD pathogenesis and the development of po-
tential treatments, limitations in longitudinal measure-
ments (e.g. morphometry study of brain structures and
cognitive behavioral assessments similar to those used in
human patients) are major limitations for advancing clin-
ical applications. Unlike other available animal models,
transgenic HD monkeys develop dystonia and bradykine-
sia similar to HD patients when under stress and can be
used for clinical evaluation procedures performed on HDtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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reported in HD monkeys suggests a similarity in motor
deficits between non-human primates and human HD
[19], however, longitudinal changes in morphometric
brain MRI measurement and cognitive functions in HD
monkeys have not been reported. This report describes
a two-year longitudinal study using morphometric meas-
urement of brain structures obtained from non-invasive
magnetic resonance imaging (MRI) and cognitive behav-
ioral assessments in one of the first transgenic HD mon-
keys, rHD1 [19].
Methods
HD and control monkeys
A male transgenic HD monkey, rHD1, was created by
transfection of mature oocyte by using lentivirus carry-
ing a mutant HTT gene composed of Exon 1 of the HTT
gene with extended CAG tract under the regulation of a
human polyubiquitin C promoter as described previ-
ously [19]. rHD1 carries a single copy of the mutant
HTT transgene with 29 CAG repeats. rHD1 and four
age-matched wild-type control rhesus macaques (Males:
REm12 and RWl12; Females: RCk12 and RFk12) were
raised in the primate nursery under the same conditions
in the same room. They all received the same treatments
and procedures designed for the longitudinal study includ-
ing MRI scans at every six months and cognitive behavioral
studies. Physical measurements including body weight and
head circumference were taken monthly, but only data at
approximately six months intervals was presented.
Quantitative measurement of mHTT transcript in
peripheral blood
Total RNA isolation from the peripheral blood cells
were collected from the HD monkey and controls. In
brief, peripheral blood cell was homogenized in 500 μl
of Trizol (Invitrogen). A phenol-chloroform extraction
of the RNA was done by addition of 100 μl of chloro-
form to the Trizol homogenates followed by centrifuga-
tion at 12,000 × g for 10 minutes at 4°C. The aqueous
layer was removed for RNA precipitation overnight with
isopropanol at −20°C. The precipitated RNA was pelleted
at 12,000 × g for 30 minutes at 4°C. All RNA pellets were
washed twice with 75% ethanol and then subsequently
dissolved in water (RNase/DNase free). 750 ng of total
RNA was reverse transcribed to cDNA with the High
Capacity Reverse Transcription Kit (Applied Biosystems).
Quantitation of HTT transcript levels were evaluated
by qPCR using a custom-designed gene-specific Taqman
assay (Applied Biosystems) and reactions run on the
BioRad CFX96 cycler. HTTexon1 Taqman assay (Forward
primer: GCCGCTGCTGCCTCA; Reverse primer: TGCA
GCGGCTCCTCAG; and Probe: CCGCCGCCCCCGCC).
To determine relative expression level of mHTT transgene,Taqman assay for HTTexon26 was used (Forward primer:
GCAGCCACCAAGCAAGAG; Reverse primer: GAGAA
GAGCTGCTCCACCAT; and Probe: CAAGGCCCGGTC
CCC). All data were normalized with the geometric mean
of GAPDH and β-actin with Taqman assays.
Western blot analysis
Total proteins were extracted from different tissues and
their concentration was determined by Bradford assay
(Pierce, Inc.). Equal amounts (20–30 μg) of protein ex-
tract with loading dye were boiled prior to loading into
4-15% gradient polyacrylamide gel (Bio-Rad, Inc.). Fol-
lowing electrophoresis, proteins were transferred onto a
PVDF membrane (Bio-Rad, Inc.) using Bio-Rad’s trans-
blot followed by blocking in 5% skim milk for 2 hours.
The membrane was then incubated with primary anti-
bodies, mouse monoclonal mEM48 (1:50 dilution)(19),
and γ-tubulin (Sigma; 1:2000 dilution), followed by
secondary antibody conjugated with peroxidase (Jackson
ImmunoResearch laboratories, Inc) for detecting pro-
teins with an Amersham ECL kit (PerkinElmer, Inc.).
Rearing conditions
After delivery, they were surrogate-nursery reared in the
primate nursery of the Yerkes National Primate Research
Center (YNPRC; Atlanta, GA) according to procedures
developed by Sackett and colleagues [21] that allow nor-
mal growth as well as the development of species-specific
social skills. These procedures included daily social inter-
actions with peers, intensive human contacts, and cogni-
tive testing that began in the first weeks of life and
continued through adulthood (for additional details on
rearing conditions, see Goursaud and Bachevalier, [22]).
Their diet consisted of infant Similac formula (SMA
with iron) supplemented with banana pellets starting at
3–4 weeks old (190 mg, P.J. Noyes, Cleveland, OH).
Starting around 8 months of age, they were fed jumbo pri-
mate chow (Lab Diet #5037, PMI Nutrition International
Inc., Brentwood, MO) and fresh fruit daily. All experimen-
tal procedures were approved by the Institutional Animal
Care and Use Committee of Emory University (Atlanta,
GA) and were conformed to the NIH guide for the Care
and Use of Laboratory Animals.
MRI measurements
Longitudinal morphometric measurements using three-
dimensional T1-weighted MR images were acquired with
a Siemens 3T Trio whole body scanner (Siemens Medical,
PA, USA) with the Siemens CP extremity volume coil on
all animals. Scans were performed every six months for
two years, starting at six months of age. Animals were
immobilized with a custom-made head holder and placed
in the sphinx position. Anesthesia was maintained with
1–1.5% isoflurane mixed with O2. Et-CO2, inhaled
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ation rate, and body temperature were monitored con-
tinuously. Three-dimensional (3D) T1-weighted images
with isotropic resolution were acquired by using the
MP-RAGE sequence with the parameters: TR = 2500 ms,
TE = 3.48 ms, TI = 950 ms, FOV = 96 mm × 96 mm,
data matrix = 192 × 192, flip-angle = 8 degree, slice
thickness = 0.5 mm, 208 slices, 4 averages.
Brain volume calculation
The 3D T1-weighted images were used for the total and
regional brain volume calculation. The skull was
stripped from all images before the calculation of total
brain volume (TBV). To perform brain extraction, we
use the FSL Brain Extraction Tool (BET; http://www.
fmrib.ox.ac.uk/fsl) [23,24]. Hippocampal and striatal
(caudate and putamen) volumes were measured based on
anatomy delineated on coronal T1-weighted images across
the two structures and manually traced. Regional and TBV
volumes were then calculated by using Image 1.42q soft-
ware. For comparison, regional volume was normalized
with the TBV.
Huntington’s disease primate model rating scale
(HDPMRS) [19]
HDPMRS was modified from the Unified Huntington’s
Disease Rating Scale (UHDRS) [25], which is commonly
used for monitoring progression of HD in patients, and
to evaluate the progression of motor and cognitive
functions that classically accompany the disease. The
HDPMRS is primarily focused on monitoring the pro-
gression of motor impairment while psychological be-
haviors, such as suicidal thought and speech were
excluded. The first section of HDPMRS was focused on
motor ability and the second section was focused on
functional assessment (see Additional file 1: Table S1
for details on HDPMRS). Video recording and scoring
was performed every 12 months for 30 minutes in a
cage inside the room where the animals were housed.
Behavioral testing
All animals were tested at different points during de-
velopment to follow their neurobehavioral and motor
development and to assess functioning of different
cognitive systems. Additional file 1: Table S2 displays
the list of behavioral tasks given to each animal and the
age at which each task was administered. All behav-
ioral tasks were conducted in a sound-attenuated room
equipped with a white noise generator to reduce external
noise, except otherwise mentioned. For the 1-Pair Object
Discrimination (1-pair OD), Pattern Discrimination (PD),
24-hr Concurrent Object Discrimination (COD), Object
Discrimination Reversal (ODR), Delayed Nonmatching-to-
Sample (DNMS), Detour-reaching/barrier and VisuopatialOrientation (VS-OR), animals were transferred to a
Wisconsin General Testing Apparatus (WGTA), facing
a test tray onto which objects or equipment could be
positioned. For the Visual-Paired Comparison (VPC)
tasks, animals were placed within an enclosure facing a
TV monitor onto which pictures could be displayed.
Rewards for problem solving tasks were either peanut,
raisin, fruity gems, mini M&M, or Marshmallows, de-
pending on animal’s preference.
Infant neurobehavioral assessment scale (INAS)
The INAS is an assessment instrument developed by
Schneider and Suomi (1992) [26] to measure maturation
of a wide range of neonatal behaviors (orientation behavior,
neuromotor abilities, and temperament measures) in new-
born monkeys. This instrument was administered for 20
minutes at the following postpartum days: 5–9, 13–18,
20–25, and 27–35 days between 10:00AM and 12:00PM
in the primate nursery with dimmed lights. Three categor-
ies of behavior were tested. First, orienting responses were
elicited by a plastic toy (visual orienting) and a noise
(auditory orienting) while the infant was wrapped in a
towel and hand-held by an experimenter. Next, neuromo-
tor functions were assessed with the infant placed in a
warm flat surface and included muscle tonus, coordin-
ation, balance, response speed and spontaneous motor
activity. Finally, temperament ratings were assessed during
the orienting and neuromotor procedures and included
vocalizations, fearfulness, irritability, and consolability.
Additional file 1: Table S3 provides a description of the
behavioral measures and of the rating scale used for
each of the three categories.
Measures of stimulus-reward associations
To assess functioning of the striato-cortical loop, we used
behavioral tasks for which performance is known to be
affected by lesions of the striatum [27-29]. In addition,
given that we needed to measure striatal-dependent func-
tions across development, stimulus-reward association
learning tasks used at each age increased in difficulty from
the simplest 1-pair OD given at 4 and 8 months to the
more challenging pattern discrimination (PD) given at 8
months and 20-pair concurrent discrimination (COD) at 9
months of age. (Please see Additional file 2 for detailed
procedures).
Measure of flexible behavioral and cognitive inhibition
and impulsivity
To assess the functioning of the frontal cortex, we use
two sensitive tasks: object discrimination reversal (ODR)
and Detour-reaching/barrier task at 12 months and 16
months, respectively. (Please see Additional file 2 for
detailed procedures and Additional file 1: Table S4).
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functions
Sensitive measures of medial temporal lobe and hippo-
campal functions were assessed with two recognition
memory tasks: VPC tasks (1, 4, and 8 months) and
DNMS (16 months). (Please see Additional file 2 for
detailed procedures).
Measures of visuospatial abilities
To assess the contributions of the frontal-striatal system
to fine motor control and associative learning, we use
VS-OR (or lifesaver task) at 16 months of age. (Please
see Additional file 2 for detailed procedures).
Results
Expression of mutant HTT in peripheral blood and
lymphoblast cell lines
rHD1 carries a single copy of the mutant HTT gene with
human exon1 and 29 CAGs regulated by the polyubiqui-
tin C promoter [19]. Wild-type rhesus macaques carry
an average of 10–11 CAGs [30]. Expression of mutant
HTT was measured in peripheral blood cells by Q-PCR
(Figure 1a). Mutant HTT transcript was approximately
one fold higher than the endogenous HTT level in com-
parison to the control monkeys while it remained at
similar levels as the disease progressed over the two-year
period. Soluble form mutant HTT protein was detected
in lymphoblast cell lines established at four time points
(9, 12, 18 and 24 months) by western blot analysis, but
robust oligomeric mutant HTT aggregates were not
observed compared to control monkey lymphoblast cells
(Figure 1b).
HD primate model rating scale (HDPMRS; Additional
file 1: Table S1)
rHD1 has a total score of 6 versus an average of 1 (0, 0, 2
and 2) for the controls at 24 months of age while a score
of “0” was recorded for rHD1 and control monkeys at 12
months of age. rHD1 scores were mainly in lower limb
dystonia. He also had several episodes of tonic-clonic
seizure at around 22 months of age when under stress
such as in transfer cage during cage wash.
Physical measurements
rHD1 had growth trajectory in body weight (Figure 1c)
and head size (Figure 1d) similar to the four wild type
controls through the first two years of age. Among the
control monkeys, only one female (RCk12) had a lower
body weight and smaller head size compared to rHD1.
Morphometric measurement of striatal and hippocampal
volumes
When controlled for TBV, the hippocampal volume in
rHD1 showed a similar growth pattern as the controls,but was smaller as compared to controls, except for one
female control (RFk12) (Figure 1e). The slight reduction
of hippocampal volume in rHD1 became more pro-
nounced at 24 months of age (Figure 1e). Striatal volume
of rHD1 showed a similar developmental trajectory as
the controls (Figure 1f ) with an overall smaller striatal
size across all ages.
Infant Neurobehavioral Assessment Scale (INAS) [26]
Figure 2 illustrates scores of rHD1 and scores of the four
control animals for orientation responses, neuromotor
responses, motor activities, and temperament on the
INAS scale during the first five weeks of life. rHD1 had
scores comparable to those of controls for all measures,
except orientation responses. rHD1 demonstrated
weaker visual and auditory orienting responses during
the first two weeks after birth compared to controls.
However, his orientation responses returned to control
levels by weeks three to five.
Measures of stimulus-reward associations
To reach criterion in the one-pair object discrimination
at four months, rHD1 made 50 errors, which is similar
to control animals (zero, seven, 24, and 106 errors).
Again, when retested on a new discrimination problem
at eight months of age, rHD1 performed even better
than controls, relearning the task immediately (zero
errors) as compared to the four control animals that
averaged 60 errors (SEM: 30.0). Thus, rHD1 acquired
simple object discrimination problems at the same rate
as controls at both four and eight months (data not
shown). For acquisition of a pattern discrimination prob-
lem at eight months, rHD1 was slightly delayed as com-
pared to the four control animals, making 208 errors to
reach criterion as compared to 38 to 173 errors for the
controls (Figure 3a). At nine months of age, rHD1 failed
to reach criterion of the 20 concurrent discrimination
problems in the limit of testing, whereas all four controls
reach criterion. The impairment in rHD1 was reflected by
the increased number of errors committed (300 errors,
Figure 3b) as compared to the four controls (66 to 242
errors).
Measure of flexible behavioral and cognitive inhibition
and impulsivity
Both object discrimination reversal task and detour-
reaching/barrier task are sensitive tasks to measure func-
tioning of the prefrontal cortex. At 12 months of age, all
animals, including rHD1, learned the initial object dis-
crimination reversal problems rapidly (0, 3, 16, 16 errors
for the controls and 4 errors for rHD1). During the six
reversals, again rHD1 performed as well as controls,
totaling 398 reversal errors and 119 perseverative errors
as compared to an average of 548 (range: 300–750)
Figure 1 Expression pattern of mutant HTT and brain volumetric measurements in a transgenic HD monkey and control monkeys.
(a) Quantitative measurement of mutant HTT transcript in controls and rHD1 peripheral blood at four time-points by quantitative PCR, (b) Western
blot analysis of one of the control monkeys and rHD1 at various time points. Arrow indicates the expression of soluble form mutant HTT protein
that was not observed in control monkey samples. (c) Longitudinal measurement of body weight. (d) Longitudinal measurement of head
circumference. Longitudinal morphometric measurements of (e) hippocampus and (f) striatum at four time-points by MRI normalized with
total brain volume.
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errors for the controls (Figure 3c). On the other hand, at
16 months of age, rHD1 performed as well as the con-
trols on the “easy” trials (Figure 3d) of the detour/barrier
task, but this animal made almost twice as many barriers
and perseverative reaches in the “moderate” (Figure 3e)
and “difficult” (Figure 3f ) trials than did control animals.
Measures of object and spatial recognition memory
functions
Sensitive measures of medial temporal lobe and hippo-
campal functions were assessed with two recognition
memory tasks, VPC and DNMS. At one month of age,rHD1 showed strong novelty preference and obtained
scores averaging 62%, 63%, 60% and 59% at 10s, 30s, 60s
and 120s delays in VPC respectively, only slightly below
those of control animals (69%, 67%, 63% and 69%). By
contrast, at four months of age, although rHD1 contin-
ued to show novelty preference scores above chance, its
scores at the longest delays of 60s and 120s were lower
than those of controls (Figure 4a). The same impairment
in recognition memory was also found in rHD1 as com-
pared to the four controls, when all animals were re-
tested at 16 months of age.
At 16 months of age, as compared to controls that
learned the DNMS task in an average of 310 trials and
Figure 2 Infant neurobehavioral assessment scale results. Scores are rated for (a) orienting responses (visual orienting and following, attention
span, auditory orienting), (b) neuromotor abilities (muscle tonus prone and supine, pull-to-sit, coordination and response speed), (c) motor activities
(locomotion and coordination), and (d) temperament (vocal reactions, fearfulness, struggle, irritability, consolability during testing) for four controls
(white bar) and rHD1. Controls are represented by mean value with SEM error bar.
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181 errors. Interestingly, in the performance test with
increasing delays, rHD1 performed as well as controls at
short delays of 30 and 60s, but his performance declined
below that of controls as the delays further increased to
120 and 600s (Figure 4b).
As shown in Table 1, in the spatial location VPC,
rHD1 obtained scores above chance levels, although his
novelty preference was weaker (59%) than that of the
four controls (range: 68%-75%). rHD1 was even more
severely impaired on the object-in-place VPC compared
to controls. In this relational spatial recognition task,
rHD1’s novelty scores were at chance levels (48%) and
lower than those of controls (range: 56%-66%). This
impairment cannot simply have resulted from the poor
visual search of all objects on the pictures, since rHD1
showed strong recognition memory in the object-control
task (61%), which also required looking at pictures
consisting of five objects.
Measures of visuospatial abilities
As shown in Table 2, as compared to controls, rHD1
appeared to show some visuospatial difficulties with the
“Easy” Routes, requiring longer time (28s) to thread the
Lifesaver out of the rods and failing to free the candy in
many more trials (18 failures) than any of the four
controls (Range: 19-24s and 4–12 failures, respectively).
However, this difference was absent in the “DifficultRoutes”, suggesting that, with further practice, rHD1
visuospatial abilities returned to the levels of those of
control animals.
Discussions
We followed the progression of symptoms and brain
maturation in the first transgenic HD monkey by
monitoring longitudinal clinical measurements of motor
functions, cognitive assessments involving several brain
networks, and morphometric measurements of brain
structures over a period of two years. rHD1 has similar
growth trajectory compared to the control monkeys
based on body weight gain (Figure 1c) and head size
(Figure 1d). While weight loss occurs in HD patients
despite adequate or even increased caloric intake [31,32],
we expect weight loss in HD monkey may be revealed as
disease progresses. A recent study of children at risk of
HD showed a significant correlation between expanded
polyQ and lower measurement of head circumferences,
weight and body mass index [33], which differed from our
observation. However, the growth trajectory of preHD
children was not different from the controls [33]. No chil-
dren with JHD were included in the study, which may
account for the difference with rHD1 that had clinical
development similar to human JHD. Although similar
growth trajectory was observed between HD and control
monkeys, the current study is based on the observation of
a single HD monkey and more conclusive information
Figure 3 For measures of stimulus-reward associations and flexible behavioral inhibition, scores are the number of errors committed
until reaching the criterion for (a) pattern discrimination at eight months, (b) concurrent discrimination at nine months and (c) object
discrimination reversal at 12 months for the four controls and rHD1. For measures of cognitive inhibition and impulsivity, scores are
number of total reaches, barrier reaches and perseverative reaches during the (d) “Easy” trials (box opened left or right and reward positioned at
the box entrance), (e) “Moderate” trials (box opened right or left and reward positioned mid-way inside the box), and (f) “Difficult” trials (box
opened right or left and reward positioned on the opposite side of the box) for the four controls (Mean ± SEM, open bars) and rHD1 (solid bars).
Figure 4 The impairment in hippocampal-dependent memory functions in rHD1. Scores are percent correct when looking at novel objects
at four different delays (a) 10s, 30s, 60s, 120s in the VPC (Visual Paired Comparison) task at four months and (b) percent correct at delays of 30s,
60s, 120s, and 600s in the DNMS (Delayed Nonmatching-to-Sample) task at 18 months for the four controls (open circle and dashed line) and
rHD1 (close circles and solid line). Controls are represented by mean value with SEM error bar.
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Table 1 Percent looking at novel in the spatial Visual
Paired Comparison (VPC) tasks
Spatial-location Object-in-place Object-control
REm12 71.1 55.9 62.6
RWl12 68.8 65.8 77.6
RCk12 68.3 55.9 76.7
RFk12 75.5 58.0 63.5
rHD1 58.9 47.8 60.6
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of a group of HD monkeys with extended age. Neverthe-
less, the data demonstrate for the first time the course of
pathological changes and clinical progression in the pri-
mate model of HD.
Although cognitive behavioral assessments are import-
ant clinical measurement on the progression of HD, and
standardized tests are used, sensitive methods for
quantitative measurement of cognitive behavioral func-
tions are limited due to variations among patients and
experimental testers as well as assessment batteries
[1,5,7,8,25,34-36]. Discrepancy due to overestimation
on the sensitivity of measurements in cross-sectional
studies suggests the importance of unbiased longitudinal
studies for precise interpretation of the results and for
determining possible clinical applications [1,6-8,37,38].
Unlike the cognitive behavioral assessment, non-invasive
MRI provides an optimal quantitative tool for determining
anatomical changes that may associate with the disease
progression. Several recent studies have shown specific
regional atrophy in the brain, particularly in the caudate
and putamen of presymptomatic HD mutation positive
individuals or HD prodrome. MRI changes occur before
functional and motor impairments, and that progression
in MRI changes is correlated with development and
progression of functional and motor impairments
[1,7,8,37,39-43]. The hippocampus, which is criticalTable 2 Visuospatial-orientation task
Mean time (sec) Fastest time (sec) Failures
Easy routes
REm12 19.71 1.87 5
RWl12 20.38 0.88 11
RCk12 19.37 2.13 4
RFk12 24.57 0.71 12
rHD1 28.61 3.83 18
Difficult routes
REm12 25.67 4.25 1
RWl12 53.47 1.75 11
RCk12 31.34 4.00 3
RFk12 68.39 1.03 12
rHD1 49.17 4.70 4for spatial and relational memory, is also reduced in
pre-manifest HD and early HD [37,44-46]. Recent lon-
gitudinal studies on pre-manifest and early stage HD
patients demonstrate significant progressive atrophy in
the caudate, putamen, thalamus and nucleus accumbens
[7,8,37,39,40,43,47,48]. The progression in brain atrophy
paralleled the decline in cognition and motor functions in
early HD [7,8,35]. These studies suggest that quantitative
longitudinal neuroimaging is a powerful tool for differ-
entiating pre-manifest and early stage HD and can be
correlated with functional and motor measurements
for monitoring disease status and progression rate
[7,8,37,39,40,43,47,48].
A similar pattern of disease progression was observed
in morphometric measurement of the striatal and hippo-
campal regions and in the decline of cognitive functions
associated with these two brain regions in rHD1. The
overall volume of both hippocampus and striatum was
smaller in rHD1 at all ages. However, the head size of
rHD1 was smaller at 5 months of age but continued to
grow and was comparable to three of the four control
monkeys up to 2 years of age except for one female
control (RCk12) with a smaller head size. The cognitive
decline was in fact present earlier than volumetric
changes in the striatum and hippocampus, when no
obvious motor deficits were yet noticed. Indeed, rHD1
had a HDPMRS score of six versus an average of one for
the controls at 24 months. rHD1 scores were mainly in
dystonia, which occurred during cognitive testing when
he was transferred into a testing apparatus at a different
location. An episode of seizure occurred at 22 months of
age during the time of cage cleaning. In general, motor
dysfunction and seizure often occurred when rHD1 was
under stressful conditions. Cognitive changes were first
clear at eight months of age; in this species, 48 months
is considered adulthood. Developmental trajectory be-
tween rhesus macaques and humans is an estimation of
1 year old monkey vs 4 years old humans, respectively.
Given the age of rHD1, the imaging findings and pro-
gressive development of cognitive behavioral decline,
especially seizures, this particular animal may parallel
human juvenile onset HD (JHD) even only with a small
expansion of polyglutamine (29Q) compared to normal
rhesus macaque (10-11Q) at the HTT gene. JHD patients
have motor symptom onset younger than age 21, with a
higher incidence of seizures in very young onset cases and
stiffness, parkinsonism, and dystonia outweighing chorea
especially in very young onset cases [49-54]. Seizures are
unusual in adult onset HD [49]. Imaging data in human
JHD is very sparse, with caudate atrophy being the most
consistent finding [55-58], which parallels with our find-
ings that reduction in caudate volume was more profound
compared to the putamen. rHD1 does exhibit chorea, but
also exhibits early cognitive decline and seizures.
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concurrent discrimination learning that were present
and detectable as early as eight and nine months of age
(Figures 3a, b), suggesting striatal dysfunction that pre-
ceded the striatal atrophy detectable by 24 months of
age (Figure 1f ). This impairment was reminiscent of the
impairment in pattern recognition memory found in HD
patients in early stages of the disease, which has been
associated with ventrocaudal striatum dysfunction [45].
Longitudinal studies over the full range of clinical mani-
festation stages are essential for determining the progres-
sion of disease, to identify biomarkers, and to develop
novel therapeutic targets. There are longitudinal studies in
humans, some ongoing, allowing analysis of face and
construct validity in the HD transgenic primate model.
A recent report of a 12-and-46 month longitudinal ana-
lysis indicates caudate atrophy in pre-manifested HD
patients [7,8] compared to the control group, although
similar findings have also been reported in JHD patients
[55-58]. A similar result was also observed in our trans-
genic HD monkey.
Dysfunction of the hippocampus in rHD1 became
detectable as early as four months of age and was further
demonstrated at 16 months by deficits in the delayed
non-matching task and in both VPC tasks (Figure 4),
respectively. The impairment in hippocampal-dependent
memory functions was consistent with the reduction in
hippocampal size at 24 months of age (Figure 1e). These
findings replicate the hippocampal-dependent memory
deficits found in HD patients even before the onset of
motor symptoms [5,7,8,45,59,60], which have also been
reported in all analyzed mouse models of the disease
[11,20,44,61].
Frontal cortical deficits present in HD patients [62,63]
were also apparent in rHD1 at 16 months of age, as
shown by increased cognitive impulsivity (increased bar-
rier and perseverative reaches) in the Detour-Reaching
task (Figure 3 Right panel), indicating dysfunction of
fronto-striatal circuitry. At this same age, visuospatial
abilities were only transiently altered in rHD1 as reflected
by longer latency to free the treat and greater number of
failures to retrieve the reward; however, this deficit was
observed only when the animals were tested with the
“Easy”, but not with the “Difficult”, routes. Although this
pattern of results may indicate habituation to the task and
practice effect, it is also possible that greater impairment
in visuospatial function may emerge later during the
progression of this animal’s disease state. Interestingly,
decline in visuospatial abilities during the HD pro-
dromal phase has not been consistently reported in the
literature, but when present, it is often found in pa-
tients closer to disease onset (see for review Papp et al.,
[64]). Finally, rHD1 showed normal performance on the
simple discrimination reversal task, consistent with thespared simple reversal learning abilities found in early
HD patients [45].
Conclusions
To summarize, our results demonstrate disease progres-
sion of a transgenic HD monkey based on longitudinal
cognitive behavioral assessments and volumetric MRI
measurements. The progression of rHD1 is closer to ju-
venile onset HD than adult onset with the development
of seizures, early impact on cognition and mild motor
impairment [49-54]. We acknowledged that additional
animals need to be prepared and studied using the same
behavioral and cognitive tasks as well as neuroimaging
procedures across development. However, given the
length of time it requires to produce this type of animals
and to assess behavioral and brain changes across devel-
opment, we believe that the longitudinal study on this
first transgenic HD monkey is encouraging and import-
ant, and suggest their potential role in understanding
HD pathogenesis, identifying biomarkers and as a pre-
clinical animal model for developing new therapeutics.
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